Ocular Myasthenia Gravis

Overview

Ocular myasthenia gravis (OMG) is an autoimmune disorder of the neuromuscular junction in which pathogenic antibodies (most often against the postsynaptic acetylcholine receptor, AChR) impair signal transmission at the motor end plate, producing fatigable weakness confined to the extraocular and eyelid muscles.¹ OMG is often called a "great masquerader" in neuro-ophthalmology because it can mimic nearly any pattern of ptosis or ocular misalignment, including patterns that resemble individual cranial nerve palsies or internuclear ophthalmoplegia, without actually following a single nerve's anatomic distribution.

Epidemiology & Risk Factors

Myasthenia gravis can present with symptoms confined to the ocular muscles (OMG) or with more widespread involvement (generalized MG, gMG); systemic generalization from initially ocular-only disease occurs frequently.¹ Approximately half of patients with OMG progress to generalized disease, most commonly within two years of onset.² Recognized predictors of generalization include AChR antibody seropositivity, abnormal repetitive nerve stimulation findings, older age at onset, presence of thymoma, and greater initial disease severity; early, frequent relapse of ocular symptoms in the months after diagnosis has also been proposed as a potential additional predictor of eventual generalization, based on case-level observation.²

Pathophysiology

In AChR-antibody-positive MG, circulating autoantibodies bind postsynaptic acetylcholine receptors at the neuromuscular junction, leading to receptor internalization, complement-mediated end-plate damage, and a reduced safety margin for neuromuscular transmission. Because this safety margin is already relatively narrow in the extraocular muscles compared with skeletal muscle elsewhere, ocular muscles are disproportionately susceptible to early, isolated involvement — the biological reason OMG so often precedes any systemic symptoms.¹ The resulting muscle end-plate dysfunction produces the hallmark clinical feature of fatigable weakness: strength that is relatively preserved at rest or with brief effort but declines with sustained or repetitive use.¹

Clinical Presentation

Patients typically report variable, fluctuating ptosis and/or diplopia that characteristically worsens through the day, with sustained effort (e.g., prolonged reading or driving), or with fatigue, and improves with rest. Diplopia can be horizontal, vertical, or oblique, and — unlike a single cranial nerve palsy — the pattern of misalignment can shift over the course of an exam or between visits, which is itself a diagnostic clue. Bilateral, asymmetric ptosis that varies in severity between the two eyes over time is a particularly characteristic presentation.

Exam Findings

• Fatigable ptosis: worsening lid position with sustained upgaze (the "fatigue test")
• Cogan's lid twitch: a brief overshoot upward twitch of the ptotic lid when the eye moves from downgaze back to primary position
• Variable, non-anatomic pattern of extraocular movement restriction that does not fit a single cranial nerve distribution
• Improvement in ptosis or ocular alignment after an ice pack is applied to the closed eyelid for a few minutes (the ice-pack test), reflecting improved neuromuscular transmission at lower temperature
• Pupils are characteristically spared — normal pupillary size and reactivity, in contrast to a pupil-involving CN III palsy

Classification

• Ocular myasthenia gravis (OMG): weakness confined to extraocular and eyelid muscles
• Generalized myasthenia gravis (gMG): involvement extending to bulbar, limb, or respiratory muscles
• Myasthenic crisis: the most severe manifestation, with respiratory muscle involvement causing life-threatening hypoxemia that requires critical care monitoring and, often, invasive ventilation¹
• By antibody status: AChR-antibody-positive, muscle-specific kinase (MuSK)-antibody-positive, and seronegative (antibody-negative) subtypes, which can differ in clinical course and treatment response

Differential Diagnosis

• Chronic progressive external ophthalmoplegia and other mitochondrial myopathies (typically symmetric, slowly progressive, without fatigability or fluctuation)
• Thyroid eye disease (restrictive myopathy, typically with proptosis and lid retraction rather than ptosis)
• Cranial nerve palsies (CN III, IV, VI — each follows a specific, reproducible anatomic pattern, unlike the variable pattern of OMG)
• Internuclear ophthalmoplegia
• Orbital or cavernous sinus vascular lesions: a cavernous sinus dural arteriovenous fistula has been reported to closely mimic OMG, including an initially positive edrophonium test with transient improvement on immunotherapy, only for atypical findings — persistent diplopia and new conjunctival injection — to eventually prompt neuroimaging that revealed the true diagnosis, underscoring that atypical ocular surface signs (conjunctival injection, chemosis) in a presumed OMG patient warrant reconsideration of the diagnosis.³

Management

Diagnosis relies on the clinical history of fluctuating weakness with diurnal variation, supportive bedside signs (fatigability, Cogan's lid twitch, ice-pack test), and confirmatory serology (AChR and, when negative, MuSK antibodies) and electrophysiologic studies (repetitive nerve stimulation, single-fiber EMG), the latter particularly useful when serology is unrevealing but clinical suspicion remains high.¹ All patients with a confirmed MG diagnosis should undergo chest imaging (CT or MRI) to screen for thymoma, regardless of whether disease is ocular or generalized at presentation.¹

Management is multimodal: acetylcholinesterase inhibitors (e.g., pyridostigmine) are typically first-line for symptomatic control, with immunomodulatory therapy — corticosteroids and steroid-sparing agents — added for inadequate response or higher-risk features (e.g., predictors of generalization). Intravenous immunoglobulin or plasma exchange is reserved for more severe or refractory presentations, and thymectomy is considered in select cases, particularly with thymoma or in younger AChR-positive patients with generalized disease.¹ Ongoing relapses of ocular symptoms despite treatment — as in a reported case with recurrent diplopia and ptosis at two and four months, preceding generalization to respiratory and bulbar involvement by month seven — should prompt close monitoring for impending generalization and reconsideration of the treatment strategy, rather than being managed as a series of isolated flares.²

Complications

• Progression from ocular to generalized disease, occurring in roughly half of patients, usually within two years
• Myasthenic crisis with respiratory failure requiring intubation and critical care
• Chronic diplopia or ptosis affecting quality of life despite treatment
• Diagnostic delay or misdiagnosis when an alternative condition (such as a cavernous sinus vascular lesion) closely mimics the clinical and even bedside-test findings of OMG³

Clinical Pearls

• Fatigability, Cogan's lid twitch, and a positive ice-pack test are useful bedside clues, but a normal pupil in the setting of variable ptosis/diplopia is one of the most useful features distinguishing OMG from a pupil-involving CN III palsy.
• All confirmed MG patients — ocular or generalized — should have chest imaging to screen for thymoma, not just those with additional systemic symptoms.¹
• Roughly half of OMG patients generalize, usually within two years; predictors include AChR seropositivity, abnormal repetitive nerve stimulation, older age, thymoma, and greater initial severity — a useful framework for counseling and monitoring intensity.²
• Even a positive edrophonium test does not guarantee the diagnosis is OMG — atypical findings such as conjunctival injection or chemosis should prompt reconsideration and neuroimaging to exclude a vascular mimicker such as a cavernous sinus dural arteriovenous fistula.³

Common Pitfalls

• Anchoring on an initial diagnosis of OMG despite atypical findings (conjunctival injection, chemosis, poor or transient response to immunotherapy) rather than reconsidering the differential.³
• Managing recurrent ocular flares as isolated events rather than recognizing that early, frequent relapse may signal impending generalization requiring closer monitoring.²
• Omitting chest imaging for thymoma screening in a patient with apparently isolated, mild ocular disease.¹
• Assuming a variable, non-anatomic pattern of diplopia must be functional or psychogenic rather than considering OMG, given how closely it can mimic other causes of fluctuating misalignment.
• Failing to monitor respiratory and bulbar function in a patient with OMG, given the possibility of progression to myasthenic crisis.¹